Immunotherapies are rapidly entering the clinic as approved treatments for diverse cancer
pathologies. Radiation therapy is an integral partner in cancer therapy, commonly as part of
complicated multimodality approaches that optimize patient outcomes. Preclinical studies
have demonstrated that the success of radiation therapy in tumor control is due in part to
immune mechanisms, and that outcomes following radiation therapy can be improved
through combination with a range of immunotherapies. However, preclinical models of …